Cargando…
Adding to the evidence or to the confusion: dual antithrombotic therapy in chronic coronary syndrome and atrial fibrillation
Autores principales: | Kany, Shinwan, Schnabel, Renate |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522448/ https://www.ncbi.nlm.nih.gov/pubmed/34385224 http://dx.doi.org/10.1136/heartjnl-2021-319830 |
Ejemplares similares
-
Genetics of atrial fibrillation—practical applications for clinical management: if not now, when and how?
por: Kany, Shinwan, et al.
Publicado: (2021) -
Eligibility for early rhythm control in patients with atrial fibrillation in the UK Biobank
por: Kany, Shinwan, et al.
Publicado: (2022) -
Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome
por: Bor, Wilbert, et al.
Publicado: (2020) -
Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?
por: Limbruno, Ugo, et al.
Publicado: (2020) -
Antithrombotic Management for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention or With Acute Coronary Syndrome: An Evidence-Based Update
por: Zhao, Shujuan, et al.
Publicado: (2021)